End Game: Adrenomed Targets Global Reach For Sepsis Candidate
German biotech Adrenomed has proof-of-concept data showing its sepsis drug can cut mortality by 67%. Now, it needs money to move the candidate into Phase IIb/III trials.
German biotech Adrenomed has proof-of-concept data showing its sepsis drug can cut mortality by 67%. Now, it needs money to move the candidate into Phase IIb/III trials.